Dement Neurocogn Disord.  2012 Jun;11(2):59-66. 10.12779/dnd.2012.11.2.59.

Subtypes of Amnestic Mild Cognitive Impairment Based on Memory Impairment Pattern and Its Potential Clinical Significance

• Yang HD
• Yang Y
• Legesse BT
• Kim S
• Alzheimer's Disease Neuroimaging Initiative

• KMID: 2172236
• DOI: http://doi.org/10.12779/dnd.2012.11.2.59

Abstract

BACKGROUND
Episodic memory impairment can be subdivided into two subtypes, encoding failure vs. retrieval deficit. We defined two subtypes of amnestic mild cognitive impairment (aMCI) according to recognition performance on the memory test: aMCI with encoding failure or aMCI-E and aMCI with retrieval deficit or aMCI-R. We hypothesized that compared to aMCI-R, subjects with aMCI-E are more likely to convert to Alzheimer's disease, as encoding failure suggests that medial temporal lobes are affected early in the disease process. We also investigated whether aMCI-E can be a predictor for progression to AD.
METHODS
Using the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, a total of 397 aMCI subjects were included. APOE genotype, cerebrospinal fluid (CSF) fluid biomarkers, and a set of neuropsychological measures were also collected. Unadjusted and adjusted odds ratios were calculated to predict the conversion to AD dementia. The Spearman's rs test was used to measure the degree of correlation between aMCI subtypes and the prognostic factors for progression to AD.
RESULTS
Among the 397 subjects, 209 (52.6%) subjects were classified into aMCI-E and 188 (47.4%) into aMCI-R. One hundred two (48.8%) subjects with aMCI-E and 57 (30.3%) of those with aMCI-R progressed to AD (unadjusted odds ratio=2.19 with 95% confidence interval [CI] 1.45-3.31) over 3 years. However, when adjusted odds ratio by a logistic regression was calculated, probability value of aMCI-E disappeared with the odds of conversion by of 1.47 (95% CI 0.89-2.43). There were statistically significant correlations between aMCI-E subtype and MMSE, CDR Memory, RAVLT delayed recall, CSF biomarkers, and genotypes.
CONCLUSIONS
This analysis did not show that aMCI-E is an independent prognostic factor to predict the progression to AD. However, this subtype significantly correlates with other prognostic factors for progression. This may suggest that aMCI-E might be a later stage of aMCI and aMCI-R an earlier stage which might be a better target than aMCI-E for therapeutic intervention. Further studies are needed to validate this conjecture.

Keyword

Memory; Mild cognitive impairment; Alzheimer's disease; Disease progression

MeSH Terms

Alzheimer Disease
Apolipoproteins E
Biomarkers
Dementia
Deoxycytidine
Disease Progression
Genotype
Logistic Models
Memory
Memory, Episodic
Mild Cognitive Impairment
Neuroimaging
Odds Ratio
Temporal Lobe
Apolipoproteins E
Deoxycytidine

Reference

1. Farias ST, Mungas D, Reed BR, Harvey D, DeCarli C. Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts. Arch Neurol. 2009. 66:1151–1157.

2. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001. 58:1985–1992.

3. de Mendonça A, Guerreiro M, Ribeiro F, Mendes T, Garcia C. Mild cognitive impairment: focus on diagnosis. J Mol Neurosci. 2004. 23:143–148.

4. Dubois B, Albert ML. Amnestic MCI or prodromal Alzheimer's disease? Lancet Neurol. 2004. 3:246–248.

5. Lopez OL, Jagust WJ, DeKosky ST, Becker JT, Fitzpatrick A, Dulberg C, et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol. 2003. 60:1385–1389.

6. Visser PJ, Scheltens P, Verhey FR, Schmand B, Launer LJ, Jolles J, et al. Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. J Neurol. 1999. 246:477–485.

7. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993. 261:921–923.

8. He J, Farias S, Martinez O, Reed B, Mungas D, Decarli C. Differences in brain volume, hippocampal volume, cerebrovascular risk factors, and apolipoprotein E4 among mild cognitive impairment subtypes. Arch Neurol. 2009. 66:1393–1399.

9. Petersen RC, Smith GE, Ivnik RJ, Tangalos EG, Schaid DJ, Thibodeau SN, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA. 1995. 273:1274–1278.

10. Aggarwal NT, Wilson RS, Beck TL, Bienias JL, Berry-Kravis E, Bennett DA. The apolipoprotein E epsilon4 allele and incident Alzheimer's disease in persons with mild cognitive impairment. Neurocase. 2005. 11:3–7.

11. Fox NC, Scahill RI, Crum WR, Rossor MN. Correlation between rates of brain atrophy and cognitive decline in AD. Neurology. 1999. 52:1687–1689.

12. Jack CR, Slomkowski M, Gracon S, Hoover TM, Felmlee JP, Stewart K, et al. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology. 2003. 60:253–260.

13. Kantarci K. 1H magnetic resonance spectroscopy in dementia. Br J Radiol. 2007. 80 Spec No 2:S146–S152.

14. Vannini P, Almkvist O, Dierks T, Lehmann C, Wahlund LO. Reduced neuronal efficacy in progressive mild cognitive impairment: a prospective fMRI study on visuospatial processing. Psychiatry Res. 2007. 156:43–57.

15. Dickerson BC, Salat DH, Bates JF, Atiya M, Killiany RJ, Greve DN, et al. Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol. 2004. 56:27–35.

16. Miller SL, Fenstermacher E, Bates J, Blacker D, Sperling RA, Dickerson BC. Hippocampal activation in adults with mild cognitive impairment predicts subsequent cognitive decline. J Neurol Neurosurg Psychiatry. 2008. 79:630–635.

17. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006. 5:228–234.

18. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009. 302:385–393.

19. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009. 65:403–413.

20. Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009. 65:557–568.

21. Jack CR, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008. 131:665–680.

22. Blumenfeld RS, Ranganath C. Prefrontal cortex and long-term memory encoding: an integrative review of findings from neuropsychology and neuroimaging. Neuroscientist. 2007. 13:280–291.

23. Barbeau EJ, Ranjeva JP, Didic M, Confort-Gouny S, Felician O, Soulier E, et al. Profile of memory impairment and gray matter loss in amnestic mild cognitive impairment. Neuropsychologia. 2008. 46:1009–1019.

24. Jeong EH, Kim HY, Lee JH. Can we further divide amnestic mild cognitive impairment based on the pattern of memory aeficit?: A preliminary study. Dement Neurocogn Disord. 2012. 11:18–24.

25. Rabin LA, Paré N, Saykin AJ, Brown MJ, Wishart HA, Flashman LA, et al. Differential memory test sensitivity for diagnosing amnestic mild cognitive impairment and predicting conversion to Alzheimer's disease. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2009. 16:357–376.

26. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010. 74:201–209.

27. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W, et al. The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am. 2005. 15:869–877.

28. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004. 256:183–194.

29. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol. 1980. 7:486–488.

30. Sheikh J, Yesavage J. Geriatric Depression Score (GDS): recent evidence and development of a shorter version. 1986. New York, NY: The Howarth Press;165–173.

31. Weschler D. WMS-R Weschler Memory Scale Revised Manual. 1987. New York, NY: The Psychological Corporation/Harcourt Brace Jovanovich, Inc.

32. Rey A. L'examen Clinique en Psychologie. 1964. Paris, France: Presses Universitaires de France.

33. Marshall GA, Rentz DM, Frey MT, Locascio JJ, Johnson KA, Sperling RA, et al. Executive function and instrumental activities of daily living in mild cognitive impairment and Alzheimer's disease. Alzheimers Dement. 2011. 7:300–308.

34. Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, et al. Conversion of mild cognitive impairment to dementia: predictive role of mild cognitive impairment subtypes and vascular risk factors. Dement Geriatr Cogn Disord. 2006. 21:51–58.

35. Yaffe K, Petersen RC, Lindquist K, Kramer J, Miller B. Subtype of mild cognitive impairment and progression to dementia and death. Dement Geriatr Cogn Disord. 2006. 22:312–319.

36. Tabert MH, Manly JJ, Liu X, Pelton GH, Rosenblum S, Jacobs M, et al. Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment. Arch Gen Psychiatry. 2006. 63:916–924.

37. Busse A, Hensel A, Gühne U, Angermeyer MC, Riedel-Heller SG. Mild cognitive impairment: long-term course of four clinical subtypes. Neurology. 2006. 67:2176–2185.

38. Seo SW, Im K, Lee JM, Kim YH, Kim ST, Kim SY, et al. Cortical thickness in single- versus multiple-domain amnestic mild cognitive impairment. Neuroimage. 2007. 36:289–297.